{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:19:10Z","timestamp":1791357550515,"version":"4.3.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.jad.2009.12.028","type":"journal-article","created":{"date-parts":[[2010,1,25]],"date-time":"2010-01-25T02:04:45Z","timestamp":1264385085000},"page":"27-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":133,"title":["Asenapine in the treatment of acute mania in bipolar I disorder: A randomized, double-blind, placebo-controlled trial"],"prefix":"10.1016","volume":"122","author":[{"given":"Roger S.","family":"McIntyre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Alphs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Macek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Panagides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2009.12.028_bib1","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1136\/emj.2003.008870","article-title":"Value of serum prolactin in the management of syncope","volume":"21","author":"Ahmad","year":"2004","journal-title":"Emerg. Med. J."},{"key":"10.1016\/j.jad.2009.12.028_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1176\/ps.2007.58.1.85","article-title":"Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders","volume":"58","author":"Baldessarini","year":"2007","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.jad.2009.12.028_bib3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/pst.310","article-title":"The impact of missing data and how it is handled on the rate of false-positive results in drug development","volume":"7","author":"Barnes","year":"2008","journal-title":"Pharm. Stat."},{"issue":"Suppl 15","key":"10.1016\/j.jad.2009.12.028_bib4","first-page":"21","article-title":"Making optimal use of combination pharmacotherapy in bipolar disorder","volume":"65","author":"Bowden","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2009.12.028_bib5","first-page":"322","article-title":"The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder","volume":"12","author":"Calvert","year":"2006","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.jad.2009.12.028_bib6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1192\/bjp.187.6.559","article-title":"Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder","volume":"187","author":"Chisholm","year":"2005","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2009.12.028_bib7","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1177\/070674370204700809","article-title":"Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophrenia","volume":"47","author":"Chue","year":"2002","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.jad.2009.12.028_bib8","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1177\/070674370404901009","article-title":"Acceptability and disintegration rates of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder","volume":"49","author":"Chue","year":"2004","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.jad.2009.12.028_bib9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hup.852","article-title":"Do formulation switches exacerbate existing medical illness? Results of an open-label transition to orally disintegrating risperidone tablets","volume":"22","author":"Chue","year":"2007","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.jad.2009.12.028_bib10","article-title":"Olanzapine in long-term treatment for bipolar disorder","volume":"CD004367","author":"Cipriani","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jad.2009.12.028_bib11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1017\/S1461145706007413","article-title":"The armamentarium of treatments for bipolar disorder: a review of the literature","volume":"10","author":"Cousins","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2009.12.028_bib12","series-title":"Presented at: 21st Congress European College of Neuropsychopharmacology; February 3\u20137, 2008; Barcelona, Spain","article-title":"Asenapine pharmacokinetics: influence of cytochrome P450 modulators and UDP-glucuronyltransferase inhibition","author":"Dogterom","year":"2008"},{"key":"10.1016\/j.jad.2009.12.028_bib13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1089\/cap.2005.15.12","article-title":"Concomitant pharmacotherapy among youths treated in routine psychiatric practice","volume":"15","author":"Duffy","year":"2005","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.jad.2009.12.028_bib14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.clinthera.2005.02.003","article-title":"Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population","volume":"27","author":"Eaddy","year":"2005","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jad.2009.12.028_bib15","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1017\/S1461145708009231","article-title":"Treatment of bipolar disorder: a systematic review of available data and clinical perspectives","volume":"11","author":"Fountoulakis","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2009.12.028_bib16","first-page":"S29","article-title":"Effect of valproate on the glucuronidation of asenapine","volume":"83","author":"Gerrits","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jad.2009.12.028_bib17","series-title":"Clinical Global Impressions","first-page":"217","article-title":"Clinical global impressions","author":"Guy","year":"1976"},{"key":"10.1016\/j.jad.2009.12.028_bib18","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1176\/appi.ajp.161.6.1057","article-title":"Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial","volume":"161","author":"Hirschfeld","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2009.12.028_bib19","first-page":"S28","article-title":"Increased single-dose concentrations of paroxetine after coadministration of the modest CYP2D6 inhibitor asenapine","volume":"83","author":"Hulskotte","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jad.2009.12.028_bib20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/070674370805300106","article-title":"Monitoring and management of metabolic risk factors in outpatients taking antipsychotic drugs: a controlled study","volume":"53","author":"Jennex","year":"2008","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.jad.2009.12.028_bib21","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/archpsyc.62.12.1322","article-title":"Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study","volume":"62","author":"Judd","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2009.12.028_bib22","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1176\/appi.ajp.160.4.741","article-title":"Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial","volume":"160","author":"Keck","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2009.12.028_bib23","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1176\/appi.ajp.160.9.1651","article-title":"A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania","volume":"160","author":"Keck","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2009.12.028_bib24","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1185\/030079906X148616","article-title":"Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice","volume":"22","author":"Ketter","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jad.2009.12.028_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/pst.267","article-title":"Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches","volume":"7","author":"Lane","year":"2008","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.jad.2009.12.028_bib26","first-page":"41","article-title":"The effect of medication adherence on health care utilization in bipolar disorder","volume":"19","author":"Lew","year":"2006","journal-title":"Manag. Care Interface"},{"key":"10.1016\/j.jad.2009.12.028_bib27","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2009.12.028_bib28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0920-9964(02)00335-3","article-title":"The InterSePT scale for suicidal thinking reliability and validity","volume":"63","author":"Lindenmayer","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jad.2009.12.028_bib29","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1399-5618.2008.00611.x","article-title":"Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change","volume":"10","author":"Martinez-Aran","year":"2008","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2009.12.028_bib30","first-page":"388","article-title":"Treating bipolar disorder. Evidence-based guidelines for family medicine","volume":"50","author":"McIntyre","year":"2004","journal-title":"Can. Fam. Physician"},{"key":"10.1016\/j.jad.2009.12.028_bib31","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.euroneuro.2005.02.006","article-title":"Quetiapine or haloperidol as monotherapy for bipolar mania: a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial","volume":"15","author":"McIntyre","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2009.12.028_bib32","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11920-008-0012-7","article-title":"Bipolar disorder and suicide: research synthesis and clinical translation","volume":"10","author":"McIntyre","year":"2008","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.jad.2009.12.028_bib33","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1399-5618.2009.00748.x","article-title":"A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states","volume":"11","author":"McIntyre","year":"2009","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2009.12.028_bib34","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1399-5618.2009.00749.x","article-title":"Asenapine versus olanzapine in acute mania: a double-blind extension study","volume":"11","author":"McIntyre","year":"2009","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2009.12.028_bib35","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1177\/0269881106068395","article-title":"Cost effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United Kingdom","volume":"21","author":"McKendrick","year":"2007","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2009.12.028_bib36","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archpsyc.64.5.543","article-title":"Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication","volume":"64","author":"Merikangas","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2009.12.028_bib37","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0364-7722(79)90058-4","article-title":"Depressive symptoms in acute schizophrenia","volume":"3","author":"Montgomery","year":"1979","journal-title":"Prog. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2009.12.028_bib38","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.clinthera.2004.12.003","article-title":"Metabolic risk during antipsychotic treatment","volume":"26","author":"Newcomer","year":"2004","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jad.2009.12.028_bib39","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/archpsyc.58.9.844","article-title":"Excess mortality in bipolar and unipolar disorder in Sweden","volume":"58","author":"Osby","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2009.12.028_bib40","series-title":"Presented at: American Psychiatric Association; May 3\u20138, 2008; Washington, DC","article-title":"Asenapine pharmacokinetics: influence of hepatic and renal impairment","author":"Peeters","year":"2008"},{"key":"10.1016\/j.jad.2009.12.028_bib41","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4088\/JCP.v67n0401","article-title":"Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials","volume":"67","author":"Perlis","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2009.12.028_bib42","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.4088\/JCP.v67n1112","article-title":"Olanzapine versus risperidone in the treatment of manic or mixed states in bipolar I disorder: a randomized, double-blind trial","volume":"67","author":"Perlis","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2009.12.028_bib43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/01.jcp.0000169068.34322.70","article-title":"Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial","volume":"25","author":"Potkin","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2009.12.028_bib44","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.4088\/JCP.v68n1004","article-title":"Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial","volume":"68","author":"Potkin","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2009.12.028_bib45","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/0269881106059693","article-title":"Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study","volume":"20","author":"Sachs","year":"2006","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2009.12.028_bib46","series-title":"Full Prescribing Information","year":"2009"},{"key":"10.1016\/j.jad.2009.12.028_bib47","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0269881107082944","article-title":"Asenapine: a novel psychopharmacologic agent with a unique human receptor signature","volume":"23","author":"Shahid","year":"2009","journal-title":"J. Psychopharmacol."},{"issue":"Suppl 20","key":"10.1016\/j.jad.2009.12.028_bib48","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2009.12.028_bib49","first-page":"44","article-title":"The economic value of lamotrigine as a mood stabilizer: a U.S. managed care perspective","volume":"17","author":"Simons","year":"2004","journal-title":"Manag. Care Interface"},{"key":"10.1016\/j.jad.2009.12.028_bib50","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jad.2006.11.019","article-title":"Service utilization and associated direct costs for bipolar disorder in 2004: an analysis in managed care","volume":"101","author":"Stensland","year":"2007","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2009.12.028_bib51","first-page":"22","article-title":"Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 US psychiatrists","volume":"40","author":"Suppes","year":"2007","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.jad.2009.12.028_bib52","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/ajp.156.5.702","article-title":"Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group","volume":"156","author":"Tohen","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2009.12.028_bib53","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/archpsyc.57.9.841","article-title":"Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group","volume":"57","author":"Tohen","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2009.12.028_bib54","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/00023210-200317070-00003","article-title":"Suicidal behaviour in bipolar disorder: risk and prevention","volume":"17","author":"Tondo","year":"2003","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2009.12.028_bib55","doi-asserted-by":"crossref","first-page":"165","DOI":"10.31887\/DCNS.2008.10.2\/evieta","article-title":"Acute and long-term treatment of mania","volume":"10","author":"Vieta","year":"2008","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.jad.2009.12.028_bib56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jad.2006.08.017","article-title":"Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004","volume":"99","author":"Wolfsperger","year":"2007","journal-title":"J. Affect. Disord."},{"issue":"suppl 3","key":"10.1016\/j.jad.2009.12.028_bib57","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1399-5618.2005.00219.x","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies","volume":"7","author":"Yatham","year":"2005","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2009.12.028_bib58","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br. J. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032710000078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032710000078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T01:08:20Z","timestamp":1759021700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032710000078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":58,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0165032710000078"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2009.12.028","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Asenapine in the treatment of acute mania in bipolar I disorder: A randomized, double-blind, placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2009.12.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}